Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

February 22, 2024

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 64 min

Earnings Call Speaker Segments

Lawrence Keusch

executive
#1

Hello, everyone, and thanks for joining us for Teleflex Incorporated's fourth quarter 2023 earnings conference call. You can find the press release and the slides that go with this call on our website at teleflex.com. Just a note that a replay will also be posted on our website, and if you'd like to listen to it, please see this morning's press release for the specifics. With us today are Liam Kelly, our Chairman, President, and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom will each give prepared remarks, and after that, we'll take your questions. Before we get started, I want to note that certain topics we'll cover on this conference call will include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website. Please be aware that these statements are forward-looking by nature and carry risks and uncertainties, so actual events or results could differ materially. Among the factors that might cause actual results or events to differ materially are those referenced in today's press release and in our filings with the SEC, including our Form 10-K, which you can access on our website; with that, I'll hand the call over to Liam for his remarks.

Liam Kelly

executive
#2

Thank you, Larry, and good morning to all of you. During today's call, we'll go over what we achieved in the fourth quarter, share a few commercial updates, and present our financial guidance for 2024. We wrapped up 2023 on a solid note, since the momentum we experienced throughout the year carried over into Q4; Teleflex posted revenues of $773.9 million for the quarter, up 2.1% versus the prior year period, and higher by 0.7% in constant currency terms. Investors should keep in mind that the fourth quarter had 5 fewer shipping days compared with the same period a year earlier. That shipping day effect during the quarter came to roughly $57 million, which translates to about a 7.4 percentage point drag on constant currency growth relative to last year. Once you account for that shipping day effect, constant currency growth implied was 8.1% versus a year ago. Adjusted earnings per share for the fourth quarter came in at $3.38, down 4% compared with the prior year period. Utilization kept moving back toward normal seasonality over the quarter. Looking at the broader picture, we saw an environment for material inflation and supply chain that was stable to improving. These trends by and large matched what we had anticipated for the entire year; across full year 2023, performance was strong, with revenues hitting $2.975 billion, equal to 6.5% constant currency growth compared with the prior year, while adjusted earnings per share came to $13.52. Looking ahead to 2024, we expect a stable procedure environment, with seasonality consistent with pre-pandemic levels. While the Teleflex portfolio probably won't get a boost from pent-up demand, given its emphasis on critical care procedures, we do expect that staffing will keep improving over the course of the year. Supply chain conditions mostly settled down during 2023, and we look for further gains in 2024. Teleflex possesses extensive manufacturing operations around the globe, and we keep evaluating opportunities for vertical integration so that we can exercise greater control over our supply chain. Now, on the subject of inflation. During 2023, certain areas showed improvement, among them seafreight and raw materials. For 2024, our assumption includes a bit more disinflation, though we should point out that costs are still somewhat high compared with historical norms and exceed where they stood in 2023. Let's now dig further into our fourth quarter revenue results. I'll start by reviewing revenues for our geographic segments in the fourth quarter. All the growth figures I'm about to give you are on a constant currency basis and factor in the drag from having 5 fewer shipping days than we did a year ago, unless I note otherwise. In the Americas, revenue came to $450.6 million, down 1.9% year over year, held back by surgical and vascular and reflecting those 5 fewer shipping days in the quarter; worth pointing out, though, both our interventional anesthesia and interventional urology businesses managed to grow compared with a year ago despite the quarter having fewer shipping days. EMEA brought in $152.4 million in revenue, a 2.7% drop from the same period last year, pressured by anesthesia and surgical and reflecting the reduced shipping days. During this quarter, the strongest adjusted growth in shipping days originated from our urology, interventional, and vascular segments. Moving on to Asia, we recorded $88.3 million in revenue, which represents a 12.6% increase compared with the same period last year. Gains were widely distributed throughout the region, including robust double-digit improvements in Korea, India, and China. These quarterly results were driven by effective commercial execution along with healthy underlying demand. Let's now turn to our fourth quarter revenue broken down by global product category. When we discuss how the global product category performed in Q4, that will likewise be presented on a constant currency basis compared with the prior year, and it takes into account those five fewer shipping days. If you adjust for shipping days, sequential growth during the fourth quarter came in as we had anticipated, with vascular and anesthesia improving their growth rates while interventional and surgical decelerated. Turning to vascular access: revenue came in at $186.7 million, down 1.2%. Beyond the reduced shipping days, the comparison with last year's same period also carried the effect of the Endurance catheter recall we had disclosed earlier. Growth in EZ-IO and other access on a year-over-year basis set the pace for the quarter, even though the smaller number of shipping days created headwinds. One thing worth highlighting: aside from the drag from the Endurance recall, our core PICC segment grew by a double-digit rate. We still believe there's room to take share in peripheral access, and the products we're launching should contribute to that. Throughout the quarter, we kept up our launch efforts for the next-generation navigation device as well as the new PICC stylet. Now on to interventional. That segment brought in $135.6 million, a 7.2% increase compared with a year earlier. Even with fewer selling days weighing on us, we posted solid growth, which speaks to the positive momentum we have and the steady progress we're making on our growth drivers. Shifting to anesthesia. Revenue came in at $98.2 million, down 3.4% from the prior-year period. Looking at our bigger product lines, hemostatic offerings had a solid quarter, posting robust growth in the double digits. That gain was partly canceled out by softer results in atomization and ET tubes, since we're still working our way back from the recall that happened earlier in 2023. Over in surgical, we brought in $109.6 million, which is a 2% drop compared with last year, when the bar was set high. The fundamental momentum across our core surgical franchise remains healthy, and that includes our ligation lineup. For 2023 as a whole, Titan brought in more than $12 million. Turning to interventional urology, that business recorded $93 million, up 4.2%. Beginning with Palette, the company we bought in October 2023, fourth-quarter sales came in slightly ahead of what we had anticipated, and that's without any contribution from Barrigel. When it comes to UroLift, the office setting is still difficult, and we're working to bring stability to that service location. Looking overseas, UroLift revenue grew nicely in Japan, and in China our early launch work is proceeding as expected, centered on surgeon training and securing reimbursement. OEM delivered another strong quarter, as revenues rose 10.9% compared with a year earlier, reaching $82.6 million. Broad-based strength across our portfolio stood out in the quarter, with every product category posting year-over-year growth, among them continued momentum in microcatheters. In the fourth quarter, other revenue fell 10.2% versus the prior year, coming in at $68.2 million. As we mentioned before, other revenues in Q4 were affected mostly by Medline ending the MSA early in December 2023, which drove most of the drop in revenue compared with last year. That wraps up what I had to say about fourth quarter revenue results. Now for a few commercial and clinical updates. Following our October 10th, 2023 acquisition of Palette Life Sciences, I'm pleased to report that integration is proceeding as we anticipated. For selected members of our legacy UroLift sales team, we've completed the initial cross-functional product sales training, and our dual bag reps are now in the field working with clinicians. Increasing the applications for rectal spacing in prostate cancer care remains our primary objective, and we are engaging in discussions with both urologists and radiation oncologists. Barrigel stands out as a distinctive rectal spacer, with clinical evidence demonstrating its ability to substantially reduce unnecessary radiation exposure. Moving on to UroLift, we continue to build upon our expanding body of clinical evidence supporting its role as a safe and effective minimally invasive solution for BPH. In November 2023, we highlighted a newly published peer-reviewed study appearing in the Nature journal Prostate Cancer and Prostatic Diseases, which reinforces the UroLift system's position as the gold standard for minimally invasive surgical management of BPH. Findings indicated that within one year of BPH surgery, one in 20 patients might need retreatment whether they get a TURP, GreenLight Rezūm, or UroLift.

Liam Kelly

executive
#3

Also, when we looked at the twelve-month mark, the rate of procedures needed again because of complications in an outpatient setting was smallest with UroLift and largest with Rezūm. For UroLift, the mean duration until the initial complication occurred was the greatest. Looking at 5 years, the need for another treatment was smallest with TURP and statistically comparable for GreenLight and UroLift. The rate at which UroLift patients required retreatment lines up with the rates seen in published controlled trials, which highlights how durable the UroLift system is. Our ongoing emphasis remains on backing UroLift with clinical evidence, and we should mention that 8 sponsored research abstracts from us have been accepted for presentation at major urological meetings during 2024. Now shifting to news about our surgical business unit. Our launch activities are finished for the Gore Seamguard Bioabsorbable Staple Line reinforcement material, which is intended for use alongside the Titan stapler. Being able to provide synthetic buttressing material together with the distinctive characteristics of the Titan stapler ought to let Teleflex do more to meet surgeons' clinical requirements and preferences within the sleeve gastrectomy market. Finally, when we consider 2024, we will keep moving forward with our new product introductions, with multiple launches spanning our business units. Within our interventional business, we anticipate gaining FDA marketing clearance and bringing the Ringer catheter to market during the second half of 2024. Ringer features a distinctive balloon design that permits blood to pass through a vessel even while that balloon is inflated; our initial launch will carry a PTCA indication, yet enrollment is complete in a vessel perforation trial that we will use when pursuing an FDA-label expansion. In our surgical business, we expect to introduce new ligation products, among them an automated polymer clip applier, during the second half of 2024; we will additionally keep updating our laryngoscope families through a series of launches over the course of the year. Our anesthesia business unit is likewise set to bring out new products, among them updated technology in our EZ-IO business that should widen our user base, and for that we anticipate FDA approval during 2024. Once these launch, we will share additional specifics. That brings my prepared remarks to a close. At this point I would like to hand the call over to Tom, who will give a more detailed review of our fourth quarter financial results. Tom.

Thomas Powell

executive
#4

Thank you, Liam, and good morning to everyone. Since we already went over how the company performed on revenue, I'll start things off by looking at margins. Adjusted gross margin came in at 60.1% for the quarter, which represents a 10 basis point improvement over the same period a year earlier. That year-over-year gain came mainly from favorable price, the benefits of our cost improvement initiatives, reduced costs tied to logistics and distribution, and the Palette acquisition, though these were partly offset by ongoing cost inflation as well as unfavorable movements in foreign exchange rates. In the fourth quarter, adjusted operating margin reached 26.3%. The 160 basis point decline compared with a year ago was driven largely by the inclusion of Palette Life Sciences operating expenses, employee-related expenses, and investments aimed at growing the business, partly offset by the flow-through of the gross margin improvement I just mentioned. Net interest expense came to $22.5 million for the fourth quarter, up from $18.7 million in the same period last year. That year-over-year rise in net interest expense reflects interest rates that were higher than a year ago along with a larger average debt balance drawn to finance the Palette acquisition, partially offset by greater interest income. Our adjusted tax rate for the fourth quarter of 2023 was 11.6%, versus 13.6% a year earlier. This year-over-year decline in the adjusted tax rate stems mainly from more tax deductions resulting from additional amortization of R&D costs, which came about because a change in U.S. tax law required those costs to be capitalized beginning in 2022. On the bottom line, adjusted earnings per share for the fourth quarter was $3.38, which is 4% lower than a year ago. That year-over-year drop in EPS reflects dilution from the Palette Life Sciences acquisition together with the incremental borrowings tied to it. Let me now move to a few balance sheet and cash flow highlights. Cash flow from operations over the 12 months was $511.7 million, compared with $342.8 million a year earlier. The $168.9 million increase was mostly the result of lower tax payments, favorable working capital changes, and favorable operating results. Those favorable working capital changes came primarily from reduced inventory purchases, which followed the inventory buildup a year ago caused by heightened global supply chain volatility. Now on to the balance sheet. At the close of the fourth quarter, our cash balance stood at $222.8 million, versus $292 million at the end of 2022. Over the 12 months, the decline in cash is mainly attributable to payments made to fund the Palette acquisition, partly offset by net proceeds from borrowings and by operating cash flow. Net leverage at the end of the quarter was roughly 1.9 times. With the Palette Life Sciences acquisition included, our financial position remains strong and continues to give us the flexibility to carry out our long-term capital allocation strategy. Let me now turn to financial guidance. I'll begin with a couple of discrete items for 2024. First, we still expect the Palette acquisition to dilute the company's adjusted earnings per share by $0.35 in 2024. Starting in fiscal year 2025, the transaction is expected to become increasingly accretive to adjusted EPS. Next, as we've shared before, the manufacturing transition services agreement with Medline tied to our divestiture of specific respiratory assets wrapped up in December 2023. It's worth noting that Teleflex brought in $75.7 million of revenue from the MSA during 2023, and that won't be recurring in 2024. Now shifting to what we anticipate for 2024: we're looking at constant currency revenue growth of 3.75%-4.75%. That year-over-year figure accounts for losing the $75.7 million in MSA revenues, which is partially balanced out by added revenues from Palette. Now on foreign exchange — we're assuming roughly $5 million, or 15 basis points, of headwind to revenue stemming from foreign exchange translation in 2024. Within our foreign exchange outlook, we've factored in a euro to dollar exchange rate of about 1.08. When you combine the MSA revenue loss, the extra Palette sales, and foreign exchange headwinds, that adds up to roughly a 100 basis point year-over-year headwind to growth in 2024. Taking the foreign exchange outlook into account, we anticipate reported revenue growth of 3.6%-4.6% in 2024, which translates to a dollar range of $3.082 billion-$3.111 billion. Shifting to margins: we're expecting 2024 gross margin to land in the range of 60%-60.75%. Our gross margin guidance captures the year-over-year positive impacts from the MSA termination, manufacturing efficiencies, price, and the Palette acquisition, partially offset by inflation and the effect of changes in foreign currency exchange rates. For 2024, we expect operating margin in the range of 26.25%-26.75%. Our guidance reflects the flow-through of gross margin and the positive impact of restructuring, offset by including operating expenses for Palette Life Sciences and investments to grow the business. Moving to items below the line. Net interest expense should approximate $78 million for 2024. The bulk of the year-over-year increase in our net interest expense outlook stems from the impact of borrowings associated with the Palette acquisition, partially offset by planned debt repayments during 2024. Our tax rate should be approximately 12% for 2024, which reflects favorable mix offset by discrete items in 2023 that won't repeat in 2024, and the impact of Pillar 2 global minimum tax. We estimate Pillar 2 will add approximately 150 basis points to the 2024 tax rate. Now turning to earnings. We expect 2024 adjusted earnings per share in the range of $13.55-$13.95. Our adjusted EPS outlook reflects $0.35 of dilution from the acquisition of Palette, $0.26 of dilution from the termination of the MSA, and a $0.23 headwind associated with the year-over-year increase in our tax rate, primarily due to the Pillar 2 minimum tax. Regarding foreign exchange, although there's a negligible impact on revenue, the headwind to earnings per share is approximately $0.24 year-over-year. Based on current foreign exchange rates, we expect roughly half of the headwind to EPS to fall into the first quarter of 2024. Once you factor those items in, and that takes into account the drag from foreign exchange, adjusted EPS growth in constant currency comes to roughly 7% at the bottom of our guidance range and 10% at the top. We don't give guidance by quarter, but to help with your models, we're looking for first quarter reported revenues of $725 million to $730 million, with FX having a negligible year-over-year effect. That wraps up what I had prepared. I'll hand things back to Liam now for some closing comments.

Liam Kelly

executive
#5

Thank you, Tom. To wrap up, I want to emphasize three main points from Q4 of 2023. To begin with, we met the financial targets we set for 2023. Across the full year, revenues on a constant currency basis rose 6.5%, and adjusted earnings per share came in at $13.52. When measured against the guidance we initially provided for 2023, our constant currency revenue growth came in above what we had guided, while adjusted earnings per share landed at the upper end of our range. Our execution continues to be solid; we are bringing new products to market, and our margins are still healthy. Next, how we performed in the fourth quarter, together with a macro environment that is stable to improving, gives us a strong base for growth as we move into 2024. Finally, we will keep concentrating on our strategy aimed at generating durable growth. We will put money into organic growth opportunities and keep driving innovation as time goes on, grow our margins, and carry out our disciplined capital allocation strategy so as to strengthen long-term value creation. The integration of Palette is going well, and we anticipate that this acquisition will contribute meaningfully to our growth in the years ahead. That brings my prepared remarks to a close. At this point, I would like to hand the call back to the operator for Q&A.

Patrick Wood

executive
#6

Morning, and thank you for the questions. So, starting with the first one, Palette — we all spend a lot of time discussing Barrigel, which makes sense since it's the majority of the business, but clearly, along with that acquisition, you picked up several other urology assets that are somewhat smaller. And when you combine those with UroLift and Barrigel, you've got something of a platform that you're building on that side. So really my question is this: how much appetite do you fellows have over the longer term for expanding in that overall market, given that it's a fairly fragmented sector and there's considerable interest across different areas? Has that sort of thing come up in your thinking, or do you feel you're now finished with urology?

Thomas Powell

executive
#7

When it comes to UroLift back in 2017, our familiarity with the urology call point was strong thanks to the surgical side of our business. Every single radical prostatectomy performed anywhere on the planet relies on a surgical product of ours. From there, we expanded through buying Palette. Barrigel, which is used for rectal spacing, serves as the primary offering in that portfolio; during the first quarter we owned it, results came in above what we had anticipated, and we intend to keep that momentum going. Before pursuing anything else in urology, our priority is bringing Palette fully into the fold, though urology certainly remains a sector we're interested in, Patrick. Men's health especially. Certain segments of men's health are ripe for disruption. Some portions of men's health have gone many years without innovation or new technologies — much like how BPH saw no disruption at all until UroLift reached the market. So we believe there are opportunities for disruption in men's health, and it's something we're focused on — though honestly, Patrick, probably not within the coming six months, since we're in the process of integrating Palette into Teleflex. After that, though, our balance sheet is, as you're aware, in excellent condition, so we'd view that as a clear area for Teleflex to expand into.

Patrick Wood

executive
#8

That's really fascinating. Thanks. So, just to piggyback quickly — clearly, you have a bunch of product launches coming through during 2024. Some items are shifting from diluted to accretive. Inflation conditions are improving somewhat. Several factors are trending strongly your way as 2024 progresses. Does that backdrop play a role in the confidence you have regarding the 2025 LRP — not to get ahead of ourselves, but is that the broad picture behind why you remain so confident about it?

Thomas Powell

executive
#9

Yeah, I have a lot of confidence in the LRP. When you look at revenue, we hit 6.5% during the initial year. Clearly, the guidance we've provided for this year sits at 3.75%-4.75%, though that includes a 100 basis point headwind. So once you adjust for those headwinds, the underlying growth we anticipate for this year comes to 4.75%-5.75%. Moving into year two of the LRP, I'm confident we can hit the guidance we've put out there, and that becomes the launching point for the following year, which is the last year of the LRP. For me, execution is everything. We did a great job executing in 2023, and my aim is to keep performing the way we did in 2023 all the way through 2024 — at a minimum, hitting our targets every quarter and ideally surpassing them as we move through the year. On margins, I believe we'll see another step up in gross margins this year, and to be fully transparent, reaching our margin goal will be more challenging, and I think the investment community is aware of that. We've encountered more inflation than anticipated, and we acquired a fantastic asset in Palette, though that asset came with some OpEx. Even so, we believe those are the correct numbers for us, and we see a path to reaching them.

Jayson Bedford

analyst
#10

Morning, everyone. Turning to gross margin — Q4 came in solid. I'd like to dig into the outlook for 2024. In 2023, you posted 59.5%, right? My understanding was that the MSA contributes 100 basis points, plus there's Palette. Your revenue base is larger now. So what I'm really asking is this: does the entire gross margin headwind stem from FX, or are there additional pressures you're factoring in?

Thomas Powell

executive
#11

Well, regarding what you mentioned, we do receive a good advantage in 2024 from the Palette acquisition as well as from leaving the MSA. Both of those things help our gross margin. What I'd say is we are facing several headwinds. Like Liam said, inflation remains above what it was before the pandemic. And when you add up our favorable pricing, the savings we get from improving manufacturing costs, and the savings from footprint programs, those can offset the inflationary pressures plus some capitalized balances sitting on the balance sheet that will flow into the P&L during 2024. So those roughly cancel out. Beyond the inflation headwinds, we're also seeing a slight negative effect from foreign exchange.

Jayson Bedford

analyst
#12

All right, thanks. And then perhaps to add to what was just asked, regarding the urology sales push, is there any selling synergy you've noticed between Barrigel and UroLift, and is it fair to say that nothing has been included in the guidance?

Thomas Powell

executive
#13

Jason, it's safe for you to conclude that the guide includes no contribution from that. Regarding UroLift, Q4 showed a slight gain over Q3, and we're watching that quite carefully. Palette is still projected at $66 million-$68 million. Interventional urology is still expected to produce roughly 7.5% revenue growth at the midpoint. At the low end of our guide, the assumption is growth only slightly above 7%. The midpoint likewise assumes UroLift shows no quarter-over-quarter gain from quarter three. Quarter three is our reference point since it's the latest period unaffected by a day's seasonality; Q1 brings a difficult comparison immediately, yet beyond that, I'd anticipate continued gradual gains throughout the year. Still, the guidance—all of it, in my view—is suitably cautious, Jason. As I mentioned before, our aim is to deliver against it over the course of the year. Speaking as a team, we're quite confident about our capacity to hit every part of it.

Shagun Singh

analyst
#14

Thank you very much for the opportunity to ask. My question concerns the 2024 guidance. The outlook you've provided points to an increase of about 5%-6%, once the one-time headwind tailwinds you referenced are factored out, and I believe you're indicating EPS will rise around 1.5 times as fast as sales. What's behind such a cautious stance, especially regarding the top line, considering the momentum you carried out of 2024 — pardon me, 2023? I have a follow-up as well.

Thomas Powell

executive
#15

Shagun, thank you. Here's how I'd put it: we feel quite good about how things stood when 2023 came to a close in quarter four. After you account for the days, our fourth-quarter growth came in at a solid 8.1%, and across the entire year we delivered 6.5%. Let me address that, Shagun. When you take this year's guidance floor of 3.75% and add that percentage back, bringing it to 4.75%, the result is the same low-end starting point we were at twelve months ago. In my view, the guidance is sensible. It sets us up to deliver as the year progresses, and I believe it gives us room, as we move through the year as a company, to repeat what we accomplished in 2023 — that has consistently been our aim. Now, Shagun, within the guidance there are several shifting elements coming from the different business units. My expectation is that APAC, OEM, and IA and surgical will pull back slightly — surgical due to having reached the one-year mark on the Titan acquisition. Meanwhile, I'd anticipate a slight uptick in growth rate for EMEA, interventional urology, vascular, and anesthesia. As I mentioned, I feel good about how we've set our guidance, and I'm confident in our capacity to hit it.

Shagun Singh

analyst
#16

Understood. Turning to M&A, Liam, could you share your latest perspective on that, particularly regarding near-term P&L dilution versus deals that grow the top line and whether you have any appetite for adjacencies? Thanks for taking the questions.

Thomas Powell

executive
#17

Yes, thanks. Well, as I always say, firepower is the most critical element when pursuing M&A, and that's something we possess; our leverage sits at 1.9 times, which affords us considerable capacity without pushing our leverage up excessively. Dilution is something we're mindful of. Feedback from our investors has been that during 2024, unfortunately, while always acting in Teleflex's best interests, having two items land in a single year generated substantial dilution. And per Tom's walkthrough of the bridge, our underlying EPS growth is genuinely strong. Yet clearly you have the MSA, which is producing some dilution, and you also have Palette generating dilution in FX. When you total all of that, the midpoint of our growth — or rather the range of our growth — comes to 7%-10% if those were excluded; so we remain aware of that. We're active in the marketplace evaluating assets. Our M&A team is occupied, and there are appealing assets out there that we feel would be a strong fit inside the Teleflex family, and we'll keep pursuing that while keeping investor feedback on dilution in mind.

Michael Sarcone

analyst
#18

Hi there, and good morning. Mike Sarcone here, calling in from Matt. I appreciate you letting me ask a question. To start, I'd like to ask about guidance — I realize you've given us Q1, and that's a big help, but could you perhaps go into a bit more detail regarding how things phase across the year? You referenced seasonality that lines up with what we saw before COVID, I believe, yet there are plenty of variables in play, especially significant changes or fluctuations in selling days during the 2023 base period. So is there anything further you can share about your thinking on phasing over the course of the year?

Thomas Powell

executive
#19

Yes. My view is that quarter one will represent the lowest point of the year, after which you'd observe steady gains throughout the rest of the year on the revenue side, and following quarter one it would be pretty steady. The reason quarter one comes in somewhat softer is, as I mentioned, a handful of difficult comps sit within that period, but our expectation is that after you move past Q1, seasonality would return to a more typical pattern, with quarter four being the largest of the year, purely because of ordinary seasonality and patients having more procedures performed during quarter four. This has been something we've observed for quite a few years now, ever since Obamacare came into existence. That, then, would be what we expect on the revenue line.

Michael Sarcone

analyst
#20

Understood. I just have one brief thing to add on that. Whenever you mention sales getting better annually, do you figure that the third quarter might exceed the second quarter when it comes to sales dollars?

Thomas Powell

executive
#21

No, what I mean broadly is that after you clear the trough in Q1, then Q2, Q3, and Q4 should each come in higher than Q1, and because of the usual seasonal pattern, Q4 is consistently the largest quarter where revenue is concerned. Mike, what I was getting at is that Q1 would represent the bottom.

Larry Biegelsen

analyst
#22

Morning, and thanks for taking my question. Liam, how did pricing look in 2023, and what do you expect for 2024? I had one follow-up as well.

Thomas Powell

executive
#23

Yes, Larry, I appreciate the questions. Pricing had a solid year in 2023. We went past our target of 50 basis points and finished above it. For 2024, our aim is to achieve another 50 basis points, and since this would be the third year of the pricing cycle, I'm hopeful we can once again at least hit that 50 basis points.

Larry Biegelsen

analyst
#24

That's useful, and I'm grateful for it. You've just given guidance for 2024, I realize. And I appreciate what you said regarding the operating margin and the LRP — that it's somewhat difficult for 2025. So I suppose what I want to ask is whether the 7%-10% underlying EPS growth for 2024 is the correct lens through which to view 2025. Also, are there moving parts worth factoring in, such as interest expense, which I'd expect to decline from that $78 million and might serve as a solid tailwind for you? Any big-picture reflections past 2024? Thank you.

Thomas Powell

executive
#25

Yes, thank you, Larry. What I'd say is, the reason we highlight the underlying earnings per share is that, on an underlying basis, that reflects what the business is delivering. So we do hold the view that our business is quite capable of pushing that high single digits up into the double digits; and even if the operating margin targets prove a challenge, I still believe the business can achieve them. But when will that happen? Should we not reach it in 2025, we'd reach it soon after. Tom, I might ask you to offer a little detail on the interest, if that's alright.

Larry Biegelsen

analyst
#26

Sure. So regarding earnings per share and the factors that will assist us in 2025, one point is that the MSA's discontinuation brings about some dilution during 2024, and once we reach 2025, that will already be incorporated into the run rate. The same dynamic holds for Palette — we anticipate Palette turning profitable by 2025. So those will be favorable developments. We're additionally observing inflation cooling off in the market, but because of how it flows through our inventory, it takes time to work through the P&L. So if inflation patterns continue as they have been, we should realize improved advantages on that front by 2025. Then regarding interest, right now we anticipate utilizing free cash flow in 2024 to continue reducing some of our prepayable debt. So every quarter throughout the year, that will lower our outstanding debt. And in our guidance, we're likewise factoring in 3 rate cuts of 25 basis points. So as the year progresses and we head into 2025, you ought to observe a more favorable interest expense situation.

Matthew O'Brien

analyst
#27

All right. Thanks for taking the question. Just a clarification upfront so everyone on the call is clear. 5.25% at the midpoint is the constant currency growth rate assumption. When everything's adjusted, 8.5% is the midpoint for the bottom line. I just want to make sure that's fully clear.

Thomas Powell

executive
#28

Yeah, I think your math's good, Matt, as always. Those would be the adjusted top line and bottom line midpoints. Thank you for clarifying. That's good of you.

Matthew O'Brien

analyst
#29

Understood. And that happens at the beginning of the year, which is your usual pattern. Understood. So the first-quarter guidance came in above what I'd anticipated, since the comparisons are really difficult. And I realize Palette is included this year, yet the remaining portion of the business would need to perform strongly in vascular and interventional. I'm not sure whether there are additional selling days, but I'd really like to hear a bit about your confidence in the outlook for Q1 in particular. And then I believe it actually suggests a pickup in your stack growth across the rest of the year. So once more, I don't know whether that's new products and so on, but we'd really like to hear about it; and then I have one brief follow-up.

Thomas Powell

executive
#30

Yes, Matt; so our guidance would presume, if I express it in percentages, it would presume approximately 2%-3% for Q1 growth. Underlying would be 3.5%-4.2% normalized for the MSA and FX and the other moving pieces. As I mentioned before, IUB would be slightly lighter purely because of the difficult comparison. And additionally, you'd have the Palette ramp as you move through the year. Vascular would be somewhat lighter in the first quarter purely because of the recall; and to your point, the new products ramps especially in vascular matter this year as we move through the year. We've launched a number of new products into the PICCC franchise, and as they ramp through the year. Concerning our level of confidence in achieving the first quarter, we're near the back end of February, Matt, and we as a team would feel confident in our capacity to deliver in that first quarter number. And as I mentioned, we've done four for four. All of 2023, we at least reached, if not surpassed, our revenue and EPS for four quarters in a row; and as a team, we're united in the fact that we're not going to be happy until we go five for five, six for six, and ultimately eight for eight, and then reset the goal into the following year. And that's what we're planning to do.

Matthew O'Brien

analyst
#31

All right. Thanks for that. And following up on what Larry asked regarding a few of those EPS pressures you're dealing with in the current year — I doubt there's much room for improvement from Palette or the MSAs during this year, yet it appears you're set up for a significant rebound when it comes to EPS growth in the next year; so even with something like growth in the low to mid-teens range for EPS, am I completely mistaken to think that way, simply considering all of these pressures you're up against this year?

Liam Kelly

executive
#32

Well, let me say, Matt, I'd be grateful if you could show us a bit more patience and allow us to carry out 2024 before we begin providing guidance for 2025. Still, we would expect — let me return to the fundamentals. The fundamental EPS growth, when you take out the pressures, is strong and healthy; and like Tom explained, there are a handful of elements that will assist beyond that, for instance Palette along with interest, and so forth; so we'll offer guidance for 2025 somewhat later in the year, Matt, if that's okay with you.

Michael Sarcone

analyst
#33

Morning, and thanks. Liam, during the remarks you had ready, you said the company keeps evaluating chances to vertically integrate so it can tighten its grip on the supply chain. What does that actually mean? Does it signal appetite for additional deals among OEMs, or is it simply saying, "Hey, we're exploring every possible route to improve sourcing and supply chain"?

Liam Kelly

executive
#34

It's closer to the second one, Mike. What we found once the pandemic passed and disruptions to the supply chain struck was that anything sitting inside our control got handled far more effectively than anything depending on outside vendors; and certain subcomponents strike us as things we could eventually take in-house. So essentially we're examining suppliers of subcomponents that sit inside our supply chain. Margins would improve. That's certain once we internalize it, and that clearly makes it appealing too; but the second option is what your question points to.

Mike Polark

analyst
#35

Thanks for that. My next question concerns a line in the 2024 gap-to-non-GAAP reconciliation — a pension charge of $2.85. That's $150 million, if my calculation is right, which isn't a trivial figure. Could you explain what's happening here? Does this involve cash, or does it not?

Thomas Powell

executive
#36

Cash isn't involved. Basically, we're getting out of one of our pension plans, and in doing so we made it fully funded and gave pensioners the choice of a buyout; anyone who declined that buyout will have an annuity set up on their behalf. So in short, this is an exit from a pension plan, and no cash is involved.

Sam Brodovsky

analyst
#37

Hello, this is Samuel Brodovsky speaking. I'm not certain, but I was wondering what assumption regarding organic growth you factored into the guidance. Also, I'm grateful that you shared your expectation of a modest decline in OEM. What should our thinking be about that?

Thomas Powell

executive
#38

My apologies. The connection is extremely poor, and we are struggling to hear you.

Michael Sarcone

analyst
#39

what growth figure is that based on?

Sam Brodovsky

analyst
#40

is my voice coming through at this point?

Thomas Powell

executive
#41

yes, that comes through more clearly.

Sam Brodovsky

analyst
#42

Hi there. Is my voice coming through at this point?

Thomas Powell

executive
#43

All right. Much clearer now. So when you asked about growth, it was that assumption you had in mind?

Sam Brodovsky

analyst
#44

My apologies for that. Regarding the organic growth assumption that's baked into the guidance?

Thomas Powell

executive
#45

Yeah. Thanks. Sorry about that; we weren't able to hear you clearly enough. So with the Titan Stapler, our assumption is that growth will happen in 2024, though not at the levels we anticipated at the time of acquisition, to be fully candid; the effect of the GLP-1s, or a substantial share of that effect, is now reflected in our run rate following 2023. And what we expect is that growth will resume, or rather continue, during 2024; we're still proctoring surgeons. Performance of the product is extremely strong. There are no problems with the Titan product as such. And with buttress now launched, 60% of surgeons are going to use buttress. Strictly speaking, our product doesn't require it, but that's the way surgeons carry out the procedure, so having buttress opens the door for us to larger portions of the market. As recently as January, our proctoring was fully consistent with what we expected, and we keep adding new surgeons.

Sam Brodovsky

analyst
#46

Great, that's useful. And I've got one more as well. You just gave us your outlook for a slight pullback in OEM growth. What sort of magnitude should we expect for that pullback? Is it reasonable to view OEM as growing in the low double digits? Thanks.

Thomas Powell

executive
#47

Well, my view is that this will amount to what I've described as a modest pullback. Last year, then, it expanded by roughly 18% or 19%. As we keep executing, it will return to the double-digit zone, so low double digits is a decent place to start, though just keep in mind that those modest pullbacks are going to be balanced out by step-ups in areas such as vascular and anesthesia, and also in regions such as EMEA.

Anthony Petrone

analyst
#48

Morning. Appreciate you having us on, and that's a nice underlying print. Liam, perhaps we could begin with procedure volumes. We've heard quite a bit from the managed care organizations regarding MLR losses, with talk of procedures running hot. That's shown up in several of the prints. I believe the underlying figure, excluding days, for Teleflex reflects that too. So perhaps just a state of the union regarding procedure volumes, specifically in the U.S., and then I'll follow up with one question on OUS geography. Thanks.

Liam Kelly

executive
#49

Yeah. Of course, Anthony. What we're observing is solid procedure volumes within the acute hospital; that continues. We're back at pre-pandemic levels. I think we're executing well on that front. We're also gaining from a plethora of new product launches. And those launches will carry on into 2024 and help further augment what we're seeing from a procedural standpoint inside the hospital. So it's a very positive environment in the acute care hospital. And as you're aware, Anthony, that space is one we really like.

Anthony Petrone

analyst
#50

That's genuinely helpful context. Moving on to China — we keep hearing mixed reports about VBP, since different programs are being introduced across various provinces. Could you share whatever update Teleflex can offer on China VBP? And here's a bigger-picture question — I don't think this has come up much on other earnings calls, but given how intensely everyone is fixated on VBP right now, should we be building into our medium-term models the assumption that China is simply a market where prices decline over the coming three to five years, considering the current geopolitical situation? Thanks.

Thomas Powell

executive
#51

Sure — what's happening is that a number of provinces are banding together to conduct volume-based procurement tenders. So the national tender stage seems to be behind us, and what we're seeing now is provinces merging together. That pattern showed up during 2023, and we took part in a number of those tenders that year. Even as all that was unfolding, China kept delivering strong double-digit growth for Teleflex, so we've built strategies to address volume-based procurement. As far as Teleflex goes, the only things we offer in China are our most differentiated products. Our anesthesia line has a very small presence there, and our drainage urology line has virtually none. Coated CVCs, interventional, and surgical are where our main China business sits. VBP is going to have some effect. However, since our products are differentiated, Teleflex sees somewhat lower discount rates, and those are being balanced out by volume. As you're aware, we achieved positive pricing across the company, so we can definitely handle the situation in China through certain strategies we have related to volume-based procurement. I remain optimistic about China as a market for Teleflex overall, and I believe it's a geography that will deliver growth for the company over the longer term.

Craig Bijou

analyst
#52

Thank you, everyone, for fielding our questions. I'd like to begin with that high-growth product category. How much did it expand during 2023? And what should we expect in terms of growth for 2024 and also 2025? I believe Tom mentioned something regarding investments made to drive growth. Perhaps, more broadly speaking, how are you viewing the necessity of putting money behind a few of these high-growth products, and what does that mean for margins?

Thomas Powell

executive
#53

Yes. Well, our high-growth products portfolio delivered really strong results in 2023. A few contributions truly stood out. Specifically, I have in mind the intraosseous and the hemostatic portfolio. MANTA keeps right on making inroads into that market. Looking ahead at the high growth for 2024, our expectation is that high growth will expand somewhere in the neighborhood of 10% to 11.5%, maybe 12% or so, roughly that area. We anticipate the durable core will perform slightly better once more this year compared with how it did a year ago, landing in the 5%-6% range; and clearly, the offset sits in that other category on account of the MSA, which is set to fall by roughly 30% or thereabouts. As for the investment supporting it, being completely candid, Craig, it's simpler to put money behind the high growth simply because the margins there are far superior. Even accounting for the extra investment, you capture the drop-through top margin from that growth. Our investment priority has consistently been — and this has held true over the last several years — directed at those high-growth buckets, given the margin profile and the advantage it delivers to mix within our income statement.

Craig Bijou

analyst
#54

Great. As a follow-up question regarding UroLift, you mentioned the office segment continues to face certain difficulties within the U.S. How about the remaining sites of service across the U.S.? Then regarding Japan, how should we view that launch plus the growth expectations over the longer or medium term?

Thomas Powell

executive
#55

Yeah. Japan comes first, and after that I'll address the sites of service. Japan, then, is performing extremely well; it genuinely matches what we anticipated. Japan is delivering whatever we informed investors it would deliver. Execution by the team over there is going very nicely. On top of that, from a geographic standpoint, we remain quite early in Taiwan and India, and we're building up in those markets. Certainly, they are smaller. And in China, we're at a very early stage. We keep working on China, pursuing getting the product listed within the public system; and 2025 will be the inflection point for China, once we begin getting it listed across more of the products. Turning to the sites of service, once more we achieved growth in the hospital site of service during Q4, yet once more, the office, sadly, remains difficult for us purely because of the reimbursement change that was implemented there.

Kristen Stewart

analyst
#56

Hi, and thanks for taking my question. Our interventional business had a strong quarter, and on a constant currency basis it was up 15% for the full year. You said MANTA keeps performing really well. Could you say more about what's fueling that growth and how sustainable you think it is as we head into 2024?

Thomas Powell

executive
#57

Sure, Kristen. So that's one of the areas that's going to pull back a bit. And like I mentioned before, other businesses stepping up will make up for it. That's the whole reason we're a portfolio company, after all — you get these ups and downs. And they'll be up against a tough comp. MANTA faces a tough comp next year; growth will continue, but that factor will be there. We're still seeing really good growth in the pump business. The competitor who'd been off the market came back in Q3; they're also back in Q4, but even so, we keep executing well in that area. And new products are the lifeblood of this business unit; our cadence of new products is really good. We launched the GuideLiner Coast last year; the Ringer is coming later in the year. Over the next several years, we have a really strong suite of products heading into the hands of this salesforce. I'm very pleased with how the interventional business is doing. Obviously, the intraosseous OnControl sits within it. That keeps performing very well, and it had a really solid quarter four too, helping drive the growth.

Kristen Stewart

analyst
#58

Great. I simply need to confirm that I've got your remarks regarding 2025 and the LRP right; so it appears you're feeling fairly confident about reaching the gross margin figure, though operating margins will be harder to hit within that projection. Is that right?

Thomas Powell

executive
#59

Yes. That is exactly what I meant, Kristen. What I'm saying is, I believe we can arrive there, and there's a possible route for us to arrive there. Will we arrive there before 2025 wraps up? Reaching it before 2025 ends is harder; we will arrive there. It may just require a little more time for us. And once more, there's certainly a reliable route to the revenue and a reliable route to the gross margin figure. And underlying EPS, which we've discussed with a few of your coworkers, underlying EPS is reliable.

Kristen Stewart

analyst
#60

All right, I really appreciate you taking these questions.

Thomas Powell

executive
#61

Thanks, Kristen.

Mike Matson

analyst
#62

Yes, thanks. I just had a question about Palette and Barrigel. Obviously, I realize there's a significant opportunity in prostate that you're pursuing, but I believe you've mentioned the possibility of moving into additional cancer types. So could you discuss the timeline for that, and whether trials would be necessary to secure those indications?

Thomas Powell

executive
#63

Our indication expansion is underway. It's included in our model; clinical trials will be required for us to reach that point; we've started identifying and enrolling the investigators who would assist us with this. Naturally, as we develop our relationships with radiation oncologists, they'd play a central role, along with urologists, in obtaining this broader indication. I'd rather not get into specifics on this call, Mike, regarding which indication, because, as you know very well, in the city where you reside, we do have competitors.

Mike Matson

analyst
#64

Yeah, got it. Then, regarding UroLift in China, I realize you've discussed how large that market is, and clearly the population there is enormous. But could you describe the competitive situation a bit? Also, I'm not certain if government payers or insurance even cover this, or whether these BPH treatments there require patients to pay out of pocket.

Thomas Powell

executive
#65

Yeah. So the situation looks much like it does elsewhere, in that TURP remains the primary procedure performed on men in China. What's different there is they aren't quite as oriented toward pharmaceuticals, in that they'll seek out other herbal treatments instead. Still, you're correct—the population is incredibly large. How things function in China is that step one involves getting listed on every regional tender. We're currently working through that in Shanghai and Beijing. Those two large provinces would be the logical starting point. After that, you pursue reimbursement. Reimbursement, for any procedure, never covers the full expense of that procedure, Mike. Some portion always falls to the patient, and people in China generally expect to pay out of pocket whenever they visit a hospital.

Mike Matson

analyst
#66

All right, thanks.

Moderator

operator
#67

At this point, I'd like to hand things over to Lawrence Keusch so he can make some closing comments.

Lawrence Keusch

executive
#68

Thanks, Mandeep, and thanks to all of you who were with us on today's call. That wraps up the fourth quarter 2023 earnings conference call for Teleflex Incorporated.

Moderator

operator
#69

We've reached the end of the time available for questions today. This brings today's conference call to a close. We appreciate everyone for joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.